Company Presentation

1. Company Presentation Presenter Confidential

2. Ocular Therapeutix, Inc. Vision To develop innovative hydrogel-based products to serve select unmet needs in ophthalmology. Products and Pipeline • Ocular sealants • Drug-eluting punctum plugs • Injectable drug delivery depots • Better closure • Full compliance • Fewer injections Confidential

3. Ophthalmic Applications Ocular surface Anterior chamber Posterior segment Versatile and biocompatible platform technology enables numerous applications for a comprehensive ophthalmic medical device company Confidential

4. Hydrogel Ancestry Ocular Therapeutix’s polyethylene glycol (PEG) technology has been proven to be safe in the body’s most sensitive tissues: • 1,000,000+ Implants • 4 PMA Approvals • 10 CE Marks Interventional Cardiology Neurosurgery Spinal Surgery Gynecological Surgery Confidential

5. Platform Technology • Pre-formable or in situ formable hydrogels for sealing or drug delivery • Benign formulation • Isotonic • Neutral pH • Water-based (no organic solvents) • No heat generation • Controllable properties • Administration • Absorption time • Modulus • Set-up time Confidential

6. Hydrogel Sealants: ReSure™ Sealant Confidential

7. ReSure Sealant • US Pivotal Clinical Study Currently Underway • Randomized, double-masked, parallel-arm trial • Suture for control group • 488 subjects at up to 24 sites • Primary endpoint: • Clear corneal incision coverage to prevent fluid egress • Secondary endpoints: • Decreased post-operative astigmatism • Decreased stromal edema • International Status: • CE Mark approved for use over corneal, scleral, and conjunctival tissues • 3,000+ commercial used in: • Cataract • Glaucoma • Corneal • Vitreoretinal • Pediatric cataract and PK Confidential

8. Application and Sealing Strength Video courtesy of Erik Mertens, MD Medipolis Health Centre Antwerp, Belgium Confidential

9. Peer-reviewed literature Cataract Retina Glaucoma Confidential

10. ReSure SealantTarget Market Segments (US) Initial target indication Annual Surgeries: ## ASP: $$ Market Potential: $$ Future markets Confidential

11. PunctUM Plugs: • Overview • Glaucoma • Bacterial Conjunctivitis • Post-Surgical Inflammation Confidential

12. Drug-Eluting Punctum Plugs Product design: • Non-invasive placement • Tailored drug release: 1-2 weeks to 3 months • Visible for retention monitoring • Comfortable and absorbable Plug expands to conform to each individual puncta Confidential

13. Retention Monitoring Insertion Post-Insertion Confidential

14. Punctum Plugs: • Overview • Glaucoma • Bacterial Conjunctivitis • Post-Surgical Inflammation Confidential

15. Punctum plug retention* • Evaluation of a non-drug plug in 30 healthy volunteers • Plug is colored with D&C Violet #2 for enhanced visualization • 60 Day Retention: • 24/26 plugs retained • 2 plugs not visible (flushed to ensure removal and patency) • 4 plugs flushed 100% 92% % of plugs retained Days Confidential *Unaudited data

16. Planned Phase 1 Study • Prospective, single-arm trial • 20 subjects (up to 40 eyes) with open-angle glaucoma or ocular hypertension • Primary efficacy endpoints: • Retention for 30 days • Mean IOP at each timepoint • Mean IOP change from baseline • IOP percentage change from baseline • Follow-up evaluations on days 10, 20, 30, and 34 Confidential

17. Punctum Plugs: • Overview • Glaucoma • Bacterial Conjunctivitis • Post-Surgical Inflammation Confidential

18. AUC Comparisons Vigamox, t.i.d. Theoretical AUC based on labeled dosing using data on file at ORA Confidential

19. Phase I Summary • Initial safety demonstrated; no adverse events • Initial feasibility of robust drug release demonstrated • Above MIC90 at all time points through Day 7 • Above detectable levels through Day 10 • No ocular complaints (e.g. FBS, excessive tearing, stinging/burning, itching, discomfort) outside of normal post-cataract symptoms. • Overall “quiet” eyes noted by PI Confidential

20. Punctum Plugs: • Overview • Glaucoma • Bacterial Conjunctivitis • Post-Surgical Inflammation Confidential

21. Steroid Release and Hydrogel Degradation in Canines Plugs demonstrate directional drug release with zone clearance observed from portion facing punctum DexamethasonePunctum Plug T10min Day 7 Day 14 0% Released 19% Released 40% Released Day 28 Day 21 62% Released 54% Released Confidential

22. Pharmacokinetics *Based on day-14 drug levels in canines. **Based on MaxiDex (0.1%) literature data; Assumes 4x day dosing. Confidential

23. Injectable Depots: • Age-Related Macular Degeneration (AMD) (Protein) Confidential

24. Objective Develop a sustained protein drug delivery system: • Injectable (<50μL) delivery to vitreous humor • Accommodates use with a 30 gauge needle • Sustained release: 2-6 months • No interference with vision • Biocompatible • Bioresorbable Confidential

25. Challenges with Sustained Protein Delivery Processing factors leading to protein denaturation: • Changes in temperature • Changes in pH • Exposure to some organic solvents • Exposure to interfaces – oil/water or air/water, etc. Protein stability in depot after implantation: • Hydrolysis • Deamidation Confidential

26. OTX Approach • Trap and retain solid protein in the molecular mesh of crosslinkedbioabsorbablehydrogel particles • PEG chain motility interferes with dissolution of protein, keeping it in solid form, slowing release and enhancing stability • As hydrogel degrades mesh size increases and protein begins to gradually dissolve and diffuse • By blending particles of different hydrogels, release profile can be dialed in Confidential

27. Protein Particles in Hydrogel 10% IgG particles (blue) in hydrogel 10% ovalbumin particles (blue) in hydrogel • Direct incorporation of protein as a solid in non-aqueous gel • Remains as a solid after drying and addition of water • Remains solid until a path to surface develops • Direct incorporation allows high protein loading Confidential

28. Intravitreal Depot Characteristics Histologyfrom excised rabbit eye after 7 day exposure to injected hydrogel depot. Optic Nerve Retina All ocular structures examined show no histopathologic changes. Includes the cornea, lens, sclera, conjunctiva, ciliary body, iris and retina. Confidential

29. Summary Confidential

30. Products and Pipeline Confidential

31. OTX Competitive Advantage • Ability to leverage opportunities in the near-term • Development and manufacturing organization • Clinical team with several trials ongoing • US-based with commercial connections and capabilities • Deep product pipeline • Strong partnership interest from several companies • Rich intellectual property portfolio Confidential

32. Total Market Opportunity U.S. Revenue by Drug Class Billions $4.2 Billion US Market Opportunity Confidential *Based on current cataract market volume

33. Current Goals • Drug Delivery • Pursue through Phase II utility in bacterial conjunctivitis • Pursue commercial development of travoprost punctum plug programs through proof of principle, Phase II and Phase III • Conduct proof of principle study and Phase II studies to demonstrate efficacy in post-surgical ocular inflammation • Partner with companies that have drugs to treat posterior segment diseases to extend their release with OTX technology • Sealant Platform • Launch ReSure in the US with clear cornea indication in Q2 2013 Confidential

34. Strategic Priorities • OTX is focusing its internal development on: • Drug delivery systems using ophthalmic drugs that are: • Coming off patent in the near term • Suitable for ocular surface / anterior segment • Have current market share-leading positions • Hydrogel sealants • OTX is open to collaborative development in: • Back-of-the-eye applications • Sub-conjunctival injectable depots • Proprietary pharmaceuticals not in conflict with OTX current disease targets Confidential

35. Thank you. www.ocutx.com Confidential